Core Scientific’s (CORZ) “Buy” Rating Reiterated at BTIG Research

Core Scientific (NASDAQ:CORZ)‘s stock had its “buy” rating reiterated by stock analysts at BTIG Research in a report issued on Thursday, Benzinga reports. They currently have a $38.00 price objective on the stock. BTIG Research’s price objective indicates a potential upside of 183.20% from the company’s previous close.

A number of other equities research analysts have also issued reports on the company. UBS Group reaffirmed a “market outperform” rating on shares of Core Scientific in a research report on Wednesday. Capital One Financial set a $33.00 price target on Core Scientific in a research report on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Core Scientific in a research report on Friday, July 17th. Wells Fargo & Company initiated coverage on Core Scientific in a research report on Thursday, September 17th. They issued an “overweight” rating and a $28.00 price target on the stock. Finally, Rothschild & Co Redburn initiated coverage on Core Scientific in a research report on Monday, September 21st. They issued a “neutral” rating and a $16.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $31.36.

Core Scientific Price Performance

Shares of CORZ stock traded down $0.09 on Thursday, hitting $13.42. The stock had a trading volume of 9,694,314 shares, compared to its average volume of 12,563,023. The firm has a market capitalization of $4.31 billion, a P/E ratio of -3.11 and a beta of 5.49. Core Scientific has a 1 year low of $12.31 and a 1 year high of $30.46. The company’s 50 day moving average price is $17.58 and its 200-day moving average price is $21.05.

Core Scientific (NASDAQ:CORZ) last posted its quarterly earnings data on Tuesday, July 28th. The company reported ($3.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($3.26). The company had revenue of $164.20 million during the quarter, compared to analysts’ expectations of $144.83 million. On average, equities analysts forecast that Core Scientific will post -1.36 EPS for the current year.

Insider Activity

In related news, insider Todd DuChene sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $19.97, for a total value of $199,700.00. Following the completion of the transaction, the insider directly owned 1,969,101 shares of the company’s stock, valued at $39,322,946.97. This trade represents a 0.51% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last ninety days, insiders purchased 19,000 shares of company stock worth $342,290 and sold 100,000 shares worth $1,881,300. Company insiders own 1.70% of the company’s stock.

Hedge Funds Weigh In On Core Scientific

Several hedge funds have recently bought and sold shares of the company. Reliant Investment Management LLC purchased a new position in Core Scientific in the 3rd quarter valued at approximately $336,000. CoreCap Advisors LLC increased its stake in Core Scientific by 205.6% in the 3rd quarter. CoreCap Advisors LLC now owns 4,355 shares of the company’s stock valued at $70,000 after purchasing an additional 2,930 shares in the last quarter. Moody National Bank Trust Division increased its stake in Core Scientific by 83.0% in the 3rd quarter. Moody National Bank Trust Division now owns 114,699 shares of the company’s stock valued at $1,833,000 after purchasing an additional 52,039 shares in the last quarter. Byrne Asset Management LLC purchased a new position in Core Scientific in the 3rd quarter valued at approximately $225,000. Finally, Engineers Gate Manager LP purchased a new position in Core Scientific in the 2nd quarter valued at approximately $1,671,000.

More Core Scientific News

Here are the key news stories impacting Core Scientific this week:

• Positive Sentiment: Analysts continue to see substantial upside. Canaccord Genuity reaffirmed a “buy” rating with a $36 price target, while BTIG Research maintained its “buy” rating and set a $38 target. Cantor Fitzgerald also reiterated an “overweight” rating with a $39 target. These targets imply significant appreciation from recent trading levels and may support investor confidence. Canaccord Genuity Core Scientific rating
• Positive Sentiment: Core Scientific’s data-center and AI infrastructure strategy remains a key catalyst. The company’s high-density colocation business could benefit from demand for AI and high-performance computing capacity, helping explain why analysts maintain bullish targets despite recent volatility.
• Neutral Sentiment: Third-quarter results are scheduled for November 5, 2026. Management will release results before the market opens and host a conference call at 8:30 a.m. Eastern Time. Investors will likely focus on colocation growth, customer concentration, capital spending, and the outlook for AI infrastructure. Core Scientific earnings announcement
• Negative Sentiment: Insider selling adds a modest negative signal. Director Todd DuChene sold 10,000 shares for approximately $151,200, reducing his holdings by 0.85%. Although he still owns more than 1.15 million shares, the transaction may weigh on sentiment. Core Scientific insider sale
• Negative Sentiment: Tenant-related credit risk remains an overhang. Needham maintained its $35 target even as CoreWeave, a key tenant, faces credit pressure. Any deterioration in CoreWeave’s financial condition could raise concerns about customer concentration, contract execution, or payment risk. Needham Core Scientific target

About Core Scientific

Core Scientific, Inc is a digital infrastructure company that develops and operates data centers in the United States. Its business has historically centered on cryptocurrency mining, particularly the processing of transactions on the Bitcoin network, while also providing hosting and infrastructure services to other mining and technology customers.

The company is expanding its data center capabilities to support high-performance computing and artificial intelligence workloads. Its services include data center operations, power and equipment management, hosting, and related infrastructure support for customers that require substantial computing capacity.

Core Scientific was founded in 2017 and became a publicly traded company through a business combination in 2022.